SCHEMBL20147987

SCHEMBL20147987

COc1ccccc1C(=O)NC1(C)CCN(C(C)(C)C)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.50
CNR2 P34972 1/20 0.50
CTSD P07339 1/20 0.47
STAT3 P40763 1/20 0.45
P2RX7 Q99572 1/20 0.44
MCHR1 Q99705 1/20 0.44
HCN4 Q9Y3Q4 2/20 0.44
HCN1 O60741 1/20 0.44
TP53 P04637 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
RET P07949 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPT P10636 1/20 0.44
AHR P35869 1/20 0.44
GFER P55789 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20068936 0.86 HCN1 (0.55) FAAHCNR2CTSDSTAT3HCN4
SCHEMBL30848613 0.85 FAAH (0.61) FAAHCNR2CTSDSTAT3TP53
SCHEMBL21652028 0.82 CHRM5 (0.52) FAAHCNR2CTSDMCHR1HCN4
SCHEMBL20147583 0.82 HCN1 (0.57) FAAHCNR2CTSDSTAT3HCN4
SCHEMBL20147980 0.82 GAA (0.45) HCN1TP53NPC1RAB9ARET
SCHEMBL20148056 0.80 LMNA (0.48) P2RX7TP53RET
SCHEMBL20148036 0.77 RET (0.43) CNR2MCHR1RAB9ARET
SCHEMBL20068934 0.75 HCN1 (0.44) CNR2HCN4HCN1TP53RET
SCHEMBL22857088 0.75 GAA (0.43) HCN1TP53NPC1RAB9ARET
SCHEMBL20626718 0.73 KDM4E (0.45) NPC1RAB9ARETALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 FAAH 4837/4885CNR2 4423/4885CTSD 4180/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 FAAH 4837/4885CNR2 4423/4885CTSD 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.